 |
Products |  |
Diseases | | Products |
|
Trials |  |
News |  |
- || lipovirtide (LP-80) / Shanxi Kangbao Bio
Trial primary completion date: Assess the Effectiveness and Safety of Lipovirtide Combined With Nucleoside Drugs in HIV-infected Patients. (clinicaltrials.gov) - Aug 15, 2024
P2, N=64, Recruiting, Sponsor: Shanxi Kangbao Biological Product Co., Ltd.
Trial primary completion date: Jun 2024 --> Dec 2024
- ||| lipovirtide (LP-80) / Shanxi Kangbao Bio
Enrollment open: Assess the Effectiveness and Safety of Lipovirtide Combined With Nucleoside Drugs in HIV-infected Patients. (clinicaltrials.gov) - Dec 22, 2023
P2, N=64, Recruiting, Sponsor: Shanxi Kangbao Biological Product Co., Ltd.
Trial primary completion date: Jun 2024 --> Dec 2024 Not yet recruiting --> Recruiting
- |||| lipovirtide (LP-80) / Shanxi Kangbao Bio
New P2 trial: Assess the Effectiveness and Safety of Lipovirtide Combined With Nucleoside Drugs in HIV-infected Patients. (clinicaltrials.gov) - Sep 29, 2023
P2, N=64, Not yet recruiting, Sponsor: Shanxi Kangbao Biological Product Co., Ltd.
- || lipovirtide (LP-80) / Shanxi Kangbao Bio
Trial completion, Trial completion date, Trial primary completion date: Pharmacokinetics and Efficacy of Multiple Dosing of Lipovirtide for Injection in HIV-infected Patients (clinicaltrials.gov) - Sep 21, 2023
P1, N=24, Completed, Sponsor: Shanxi Kangbao Biological Product Co., Ltd.
Not yet recruiting --> Recruiting Not yet recruiting --> Completed | Trial completion date: Nov 2022 --> Sep 2023 | Trial primary completion date: Oct 2022 --> Jun 2023
- || lipovirtide (LP-80) / Shanxi Kangbao Bio
Trial completion, Trial completion date, Trial primary completion date: A Study to Assess the Safety, Tolerability and Pharmacokinetics of Lipovirtide in HIV-infected Patients (clinicaltrials.gov) - Sep 21, 2023
P1, N=46, Completed, Sponsor: Shanxi Kangbao Biological Product Co., Ltd.
Not yet recruiting --> Completed | Trial completion date: Nov 2022 --> Sep 2023 | Trial primary completion date: Oct 2022 --> Jun 2023 Recruiting --> Completed | Trial completion date: Oct 2021 --> Jul 2023 | Trial primary completion date: Aug 2021 --> May 2023
- || lipovirtide (LP-80) / Shanxi Kangbao Bio
New P1 trial: Pharmacokinetics and Efficacy of Multiple Dosing of Lipovirtide for Injection in HIV-infected Patients (clinicaltrials.gov) - Apr 26, 2022
P1, N=24, Not yet recruiting, Sponsor: Shanxi Kangbao Biological Product Co., Ltd.
- || lipovirtide (LP-80) / Shanxi Kangbao Bio
Enrollment open: A Study to Assess the Safety, Tolerability and Pharmacokinetics of Lipovirtide in HIV-infected Patients (clinicaltrials.gov) - Jul 14, 2021
P1, N=46, Recruiting, Sponsor: Shanxi Kangbao Biological Product Co., Ltd.
Recruiting --> Completed | Trial completion date: Oct 2021 --> Jul 2023 | Trial primary completion date: Aug 2021 --> May 2023 Not yet recruiting --> Recruiting
- | lipovirtide (LP-80) / Shanxi Kangbao Bio
New P1 trial: A Study to Assess the Safety, Tolerability and Pharmacokinetics of Lipovirtide in HIV-infected Patients (clinicaltrials.gov) - Oct 18, 2020
P1, N=46, Not yet recruiting, Sponsor: Shanxi Kangbao Biological Product Co., Ltd.